- Benzinga•last month
OXiGENE, Inc. (Nasdaq: OXGN ) revealed the Food and Drug Administration has granted orphan drug status to its CA4P for the treatment of glioma. According to the company, the designation provided for seven ...
We keep the tough going with 2,300 convenient locations, 6,500 helpful employees & a 97% customer satisfaction rating. Talk about strength in numbers.
- Benzinga•4 months ago
Shares of OXiGENE Inc (NASDAQ: OXGN ), a nano-cap biopharmaceutical company that focuses on the treatment of cancer, spiked higher by 13 percent on Wednesday after the company announced that the U.S. Food ...
|52wk Range||0.49 - 1.42|
|Day's Range||0.70 - 0.74|
|Avg Vol (3m)||734,905|
As of 4:00 PM EDT. Market closed.